Avoid Falsely Accusing Female Athletes Who Use Levonorgestrel of Doping
Drug Testing and Analysis · 2025
DOI: 10.1002/dta.3925 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Testing and Analysis, 2025. Verfasst von Alexander Andersson und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden. Hauptthemen laut MEDLINE: Levonorgestrel, Doping in Sports, Substance Abuse Detection. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Athletes are explicitly responsible for everything they consume, which may be an issue when the metabolic pathways of prohibited and non‐prohibited compounds intersect. This was the case when 18‐methyl‐19‐noretiocholanolone, an 18‐methyl‐19‐nortestosterone metabolite, was detected in a sample of an athlete that had used an emergency contraceptive pill containing levonorgestrel. Six women were recruited to this study to elucidate the link between 18‐methyl‐19‐noretiocholanolone and levonorgestrel. After providing a pre‐treatment urine sample, one tablet of NorLevo, 1.5 mg, was ingested and six additional urine samples were collected. The samples were analysed with GC–MS/MS after extraction and derivatisation. In all six participants, 18‐methyl‐19‐noretiocholanolone could be detected at 1.5–2.5 ng/mL with a t max of 2 h. The presence of 18‐methyl‐19‐noretiocholanolone was in all samples accompanied by levonorgestrel and its metabolite tetrahydronorgestrel, the latter being present at highest concentrations (60–300 ng/mL) up to 48 h post intake. Conclusively, this study demonstrates a metabolic link between 18‐methyl‐19‐noretiocholanolone and levonorgestrel, confirming the need to verify the absence of levonorgestrel or its markers before reporting an adverse analytical finding.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Karolinska Institutet, Stockholm, Sweden.
- Department of Clinical Pharmacology, Karolinska University Hospital, Stockholm, Sweden.
- Department of Medicine, Karolinska Institutet, Stockholm, Sweden.
ORCID-Profile: Alexander Andersson, Lena Ekström
Zitieren
APA
Andersson, A., Pohanka, A., Lehtihet, M., & Ekström, L. (2025). Avoid Falsely Accusing Female Athletes Who Use Levonorgestrel of Doping. Drug Testing and Analysis. https://doi.org/10.1002/dta.3925
Vancouver
Andersson A, Pohanka A, Lehtihet M, Ekström L. Avoid Falsely Accusing Female Athletes Who Use Levonorgestrel of Doping. Drug Testing and Analysis. 2025. doi:10.1002/dta.3925
BibTeX
@article{Andersson2025,
author = {Andersson, Alexander and Pohanka, Anton and Lehtihet, Mikael and Ekström, Lena},
title = {Avoid Falsely Accusing Female Athletes Who Use Levonorgestrel of Doping},
journal = {Drug Testing and Analysis},
year = {2025},
doi = {10.1002/dta.3925}
}
EUVIMED